Across TCGA pan-cancer cohorts, CNTN6 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CNTN6 data layer compared with 20 for mass-spec protein and 9 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher CNTN6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CNTN6 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM are the cancer types where CNTN6 mass-spec protein most reproducibly stratifies survival.